Adrenomed AG
Hennigsdorf, DE · 3 known investors
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
BiotechHealthtechMedical Devices
Founders & leadership
GM
Gerald MoellerCo-founder and former CEO
RJ
Richard JonesChief Executive Officer (CEO)
DG
David GermonpréChief Financial Officer (CFO)
Investors · 3
Frequently asked questions
- What does Adrenomed AG do?
- AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.
- Who founded Adrenomed AG?
- Adrenomed AG was founded by Gerald Moeller.
- Who are Adrenomed AG's investors?
- Adrenomed AG's investors include Brandenburg Kapital, Catalyze Capital, VU Venture Partners.
- Where is Adrenomed AG headquartered?
- Adrenomed AG is headquartered in Hennigsdorf, DE.